Stock Analysis
Natera, Inc. Common StockNTRA
Sector: Healthcare · Industry: Services-Medical Laboratories
AnalystsStrong Buy30 analystsPrice is 87% of the way from the year's low to its high.
Cash covers 1369% of debt · FY 2025.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation25
- Profitability0
Weak fundamentals at a demanding price.
Market context
-2.8% today· Z 1.4σ
Bull Case
- ✓Altman Z 48.3 — safe-zone balance sheet
- ✓Revenue CAGR 38.6% — durable top-line growth
What's happening with NTRA
Profile
Strong financial health; profitability, moat, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (0.1%)5/25
- P/S (20.9x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (38.6%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-33.0%)0/25
- ROE (-11.2%)0/25
- Net margin (-7.1%)0/25
- Operating margin (-10.7%)0/25
- Financial Health75/100 · Strong
- Altman Z (48.28)25/25
- Current ratio (3.39)25/25
- Interest coverage (-76.2x)0/25
- Net cash / debt (Net cash)25/25
- Quality33/100 · Weak
- Piotroski F (6/9)15/25
- Beneish M (-2.02)12/25
- FCF conversion (n/a)0/25
- Margin stability (σ 20.2%)6/25
- Moat20/100 · Weak
- ROIC >12% years (0/6 yrs)0/25
- Median gross margin (43.2%)20/25
- FCF-positive years (2/10 yrs)0/25
- Worst-year net margin (worst -75.4%)0/25
Risk Flags
- ⚠SBC 14.1% of revenue — real dilution cost
- ⚠10 loss-making years in recent history
- ⚠Interest coverage -76.2× — thin debt cushion
About Natera, Inc. Common Stock
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. Show more
The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Headquarters: AUSTIN, TX · Employees: 6,140 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF814.4xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
FCF Yield0.1%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -16.5%–0.6% · 69th pct · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
P/S (TTM)20.95xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.0x–22.7x · 99th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales21.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio33.12xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Elevated investment: Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
Profitability
0EROIC-33.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-11.2%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-8.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-7.1%D
Grade D: LowNet Income / Revenue
Operating Margin-10.7%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin65.2%A
Grade A: PremiumGross Profit / Revenue
FCF Margin3.1%D
Grade D: LowFCF / Revenue · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
True FCF Margin-11.0%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
Growth
25ERevenue CAGR38.6%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue14.1%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score48.28A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.39xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.74xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-76.2xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
Net Debt/EBIT3.5xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.05xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt13.69xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
33DPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.02C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income · Elevated investment — CapEx = 63% of operating cash flow, weighing on reported FCF
Margin Stability20.2%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue5.3%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.14xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Rabinowitz Matthew Filed | Rabinowitz Matthew | Gift | -6000 | |
Moshkevich Solomon Filed | Moshkevich Solomon | SellOpen market sale | -1846 | |
Moshkevich Solomon Filed | Moshkevich Solomon | SellOpen market sale | -954 | |
Moshkevich Solomon Filed | Moshkevich Solomon | SellOpen market sale | -200 | |
Chapman Steven Leonard Filed | Chapman Steven Leonard | SellOpen market sale | -1273 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sheena Jonathan Filed | Sheena Jonathan | SellOpen market sale | -220 | |
Sheena Jonathan Filed | Sheena Jonathan | SellOpen market sale | -1935 | |
Sheena Jonathan Filed | Sheena Jonathan | SellOpen market sale | -1341 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
20EROIC >12% Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)43.2%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-75.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$7.60
Cash & short-term investments per share (Finnhub)
Book Value / Share$12.68
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$80.32M
Total debt obligations (short + long term)
Cash & Equiv.$1.10B
Cash and short-term investments
Net Debt$-1.02BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$1.71B
Shareholders' equity (book value)
Asset / Liability3.50xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$56.71B
Current Market Capitalization
Beta1.54C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Natera, Inc. Common Stock (NTRA)
NTRA is down 2.80% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Natera, Inc. Common Stock. Altman Z-Score of 48.28 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Revenue has compounded at roughly 39% annually — a strong growth profile.
- Company is effectively debt-free after netting cash.
- Interest coverage of -76.2× leaves little room for earnings shocks.
- Natera, Inc. Common Stock posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, NTRA trades at a premium to its historical multiples.
See how NTRA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NTRA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 395.96 | -6.97% | -3.88 |
| Oct 6 | After-hours | 399.78 | -6.08% | -3.45 |
| Sep 22 | After-hours | 390.90 | +5.47% | 2.18 |
Frequently Asked Questions about NTRA
What is the current Natera, Inc. Common Stock (NTRA) stock price?
NTRA is trading at $393.44 at the last market close, down 2.80% on the session. PreMarketPrice tracks NTRA pre-market, intraday and after-hours prices.
Is NTRA stock a buy right now?
PreMarketPrice's quantitative model rates Natera, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NTRA stock overvalued?
Natera, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Natera, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for NTRA. The Earnings section lists recent reports and updates as dates are announced.
What sector does Natera, Inc. Common Stock operate in?
Natera, Inc. Common Stock operates in the Healthcare sector, within the Services-Medical Laboratories industry. The Related Stocks section lists sector peers for comparison.
What does Natera, Inc. Common Stock do?
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology.
About Natera, Inc. Common Stock (NTRA) Stock
Natera, Inc. Common Stock (NTRA) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry. As of the latest update, Natera, Inc. Common Stock is trading at $393.44, down 2.80% on the day with a market capitalization of $56.7 billion. The financial health score for NTRA is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NTRA stock.
NTRA Stock Analysis & Key Metrics
On PreMarketPrice, you can track Natera, Inc. Common Stock (NTRA) across multiple dimensions:
- Pre-market price & movement: Real-time NTRA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NTRA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Natera, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NTRA.
- Sector peers: Compare NTRA against 6 other healthcare stocks on key financial metrics.
Is NTRA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Natera, Inc. Common Stock (NTRA) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Natera, Inc. Common Stock (NTRA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.